Matthew K. Fust

Insider Reports History

Entity
Individual
Location
C/O Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Matthew K. Fust
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew K. Fust:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Crinetics Pharmaceuticals, Inc. Director Common Stock 21.9K $1.04M $47.49 Jun 7, 2024 Direct
Ultragenyx Pharmaceutical Inc. Director Common Stock 20.2K $909K $45.00 Jun 18, 2024 Direct
Neumora Therapeutics, Inc. Director Common Stock 20.1K $342K $17.03 Oct 18, 2024 Direct
Atara Biotherapeutics, Inc. Director Common Stock 259K $186K $0.72 Mar 31, 2024 Direct
Neumora Therapeutics, Inc. Director Stock Option (Right to Buy) 85.6K Oct 18, 2024 Direct
Atara Biotherapeutics, Inc. Director Non-Qualified Stock Option (Right to Buy) 79.5K May 31, 2023 Direct
Crinetics Pharmaceuticals, Inc. Director Stock Option (right to buy) 12.5K Jun 7, 2024 Direct
Ultragenyx Pharmaceutical Inc. Director Stock Option (Right to Buy) 9.9K Jun 18, 2024 Direct

Insider Reports Filed by Matthew K. Fust

Symbol Company Period Transactions Value $ Form Type Date Filed Role
NMRA Neumora Therapeutics, Inc. Oct 17, 2024 12 -$244K 4 Oct 18, 2024 Director
RARE Ultragenyx Pharmaceutical Inc. Jun 18, 2024 2 $0 4 Jun 20, 2024 Director
NMRA Neumora Therapeutics, Inc. Jun 13, 2024 2 $0 4 Jun 14, 2024 Director
CRNX Crinetics Pharmaceuticals, Inc. Jun 7, 2024 2 $0 4 Jun 11, 2024 Director
ATRA Atara Biotherapeutics, Inc. Mar 31, 2024 1 $0 4 Apr 2, 2024 Director
CRNX Crinetics Pharmaceuticals, Inc. Mar 20, 2024 12 -$1.39M 4 Mar 22, 2024 Director
RARE Ultragenyx Pharmaceutical Inc. Mar 7, 2024 3 -$620K 4 Mar 11, 2024 Director
NMRA Neumora Therapeutics, Inc. Sep 14, 2023 1 $0 4 Sep 18, 2023 Director
NMRA Neumora Therapeutics, Inc. Sep 14, 2023 0 $0 3 Sep 14, 2023 Director
CRNX Crinetics Pharmaceuticals, Inc. Jun 16, 2023 2 $0 4 Jun 21, 2023 Director
RARE Ultragenyx Pharmaceutical Inc. Jun 7, 2023 3 -$171K 4 Jun 9, 2023 Director
ATRA Atara Biotherapeutics, Inc. May 31, 2023 2 $0 4 Jun 2, 2023 Director
CRNX Crinetics Pharmaceuticals, Inc. Jul 13, 2022 3 -$111K 4 Jul 15, 2022 Director
RARE Ultragenyx Pharmaceutical Inc. Jun 24, 2022 2 $0 4 Jun 28, 2022 Director
ATRA Atara Biotherapeutics, Inc. Jun 23, 2022 2 $0 4 Jun 27, 2022 Director
CRNX Crinetics Pharmaceuticals, Inc. Jun 17, 2022 1 $0 4 Jun 21, 2022 Director
RARE Ultragenyx Pharmaceutical Inc. Mar 4, 2022 2 $303K 4 Mar 8, 2022 Director
ATRA Atara Biotherapeutics, Inc. Nov 4, 2021 1 -$260K 4 Nov 5, 2021 Director
CRNX Crinetics Pharmaceuticals, Inc. Nov 1, 2021 3 -$211K 4 Nov 3, 2021 Director
CRNX Crinetics Pharmaceuticals, Inc. Sep 8, 2021 3 -$143K 4 Sep 9, 2021 Director
CRNX Crinetics Pharmaceuticals, Inc. Jul 26, 2021 3 -$88.4K 4 Jul 27, 2021 Director
CRNX Crinetics Pharmaceuticals, Inc. Jul 19, 2021 3 -$88K 4 Jul 20, 2021 Director
CRNX Crinetics Pharmaceuticals, Inc. Jul 12, 2021 3 -$94K 4 Jul 13, 2021 Director
RARE Ultragenyx Pharmaceutical Inc. Jun 24, 2021 2 $0 4 Jun 28, 2021 Director
CRNX Crinetics Pharmaceuticals, Inc. Jun 22, 2021 1 $0 4 Jun 23, 2021 Director
ATRA Atara Biotherapeutics, Inc. Jun 8, 2021 2 $0 4 Jun 9, 2021 Director